Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Shavali Shaik is active.

Publication


Featured researches published by Shavali Shaik.


Nature | 2011

SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction.

Hiroyuki Inuzuka; Shavali Shaik; Ichiro Onoyama; Darning Gao; Alan Tseng; Richard S. Maser; Bo Zhai; Lixin Wan; Alejandro Gutierrez; Alan W. Lau; Yonghong Xiao; Amanda L. Christie; Jeffrey Settleman; Steven P. Gygi; Andrew L. Kung; Thomas Look; Keiichi I. Nakayama; Ronald A. DePinho; Wenyi Wei

The effective use of targeted therapy is highly dependent on the identification of responder patient populations. Loss of FBW7, which encodes a tumour-suppressor protein, is frequently found in various types of human cancer, including breast cancer, colon cancer and T-cell acute lymphoblastic leukaemia (T-ALL). In line with these genomic data, engineered deletion of Fbw7 in mouse T cells results in T-ALL, validating FBW7 as a T-ALL tumour suppressor. Determining the precise molecular mechanisms by which FBW7 exerts antitumour activity is an area of intensive investigation. These mechanisms are thought to relate in part to FBW7-mediated destruction of key proteins relevant to cancer, including Jun, Myc, cyclin E and notch 1 (ref. 9), all of which have oncoprotein activity and are overexpressed in various human cancers, including leukaemia. In addition to accelerating cell growth, overexpression of Jun, Myc or notch 1 can also induce programmed cell death. Thus, considerable uncertainty surrounds how FBW7-deficient cells evade cell death in the setting of upregulated Jun, Myc and/or notch 1. Here we show that the E3 ubiquitin ligase SCFFBW7 (a SKP1–cullin-1–F-box complex that contains FBW7 as the F-box protein) governs cellular apoptosis by targeting MCL1, a pro-survival BCL2 family member, for ubiquitylation and destruction in a manner that depends on phosphorylation by glycogen synthase kinase 3. Human T-ALL cell lines showed a close relationship between FBW7 loss and MCL1 overexpression. Correspondingly, T-ALL cell lines with defective FBW7 are particularly sensitive to the multi-kinase inhibitor sorafenib but resistant to the BCL2 antagonist ABT-737. On the genetic level, FBW7 reconstitution or MCL1 depletion restores sensitivity to ABT-737, establishing MCL1 as a therapeutically relevant bypass survival mechanism that enables FBW7-deficient cells to evade apoptosis. Therefore, our work provides insight into the molecular mechanism of direct tumour suppression by FBW7 and has implications for the targeted treatment of patients with FBW7-deficient T-ALL.


Molecular Cell | 2011

mTOR drives its own activation via SCF(βTrCP)-dependent degradation of the mTOR inhibitor DEPTOR.

Daming Gao; Hiroyuki Inuzuka; Meng Kwang Marcus Tan; Hidefumi Fukushima; Jason W. Locasale; Pengda Liu; Lixin Wan; Bo Zhai; Y. Rebecca Chin; Shavali Shaik; Costas A. Lyssiotis; Steven P. Gygi; Alex Toker; Lewis C. Cantley; John M. Asara; J. Wade Harper; Wenyi Wei

The activities of both mTORC1 and mTORC2 are negatively regulated by their endogenous inhibitor, DEPTOR. As such, the abundance of DEPTOR is a critical determinant in the activity status of the mTOR network. DEPTOR stability is governed by the 26S-proteasome through a largely unknown mechanism. Here we describe an mTOR-dependent phosphorylation-driven pathway for DEPTOR destruction via SCF(βTrCP). DEPTOR phosphorylation by mTOR in response to growth signals, and in collaboration with casein kinase I (CKI), generates a phosphodegron that binds βTrCP. Failure to degrade DEPTOR through either degron mutation or βTrCP depletion leads to reduced mTOR activity, reduced S6 kinase activity, and activation of autophagy to reduce cell growth. This work expands the current understanding of mTOR regulation by revealing a positive feedback loop involving mTOR and CKI-dependent turnover of its inhibitor, DEPTOR, suggesting that misregulation of the DEPTOR destruction pathway might contribute to aberrant activation of mTOR in disease.


Cancer Cell | 2010

Phosphorylation by Casein Kinase I promotes the turnover of the Mdm2 oncoprotein via the SCFβ-TRCP ubiquitin ligase

Hiroyuki Inuzuka; Alan Tseng; Daming Gao; Bo Zhai; Qing Zhang; Shavali Shaik; Lixin Wan; Xiaolu L. Ang; Caroline Mock; Haoqiang Yin; Jayne M. Stommel; Steven P. Gygi; Galit Lahav; John M. Asara; Zhi Xiong Jim Xiao; William G. Kaelin; J. Wade Harper; Wenyi Wei

Mdm2 is the major negative regulator of the p53 pathway. Here, we report that Mdm2 is rapidly degraded after DNA damage and that phosphorylation of Mdm2 by casein kinase I (CKI) at multiple sites triggers its interaction with, and subsequent ubiquitination and destruction, by SCF(beta-TRCP). Inactivation of either beta-TRCP or CKI results in accumulation of Mdm2 and decreased p53 activity, and resistance to apoptosis induced by DNA damaging agents. Moreover, SCF(beta-TRCP)-dependent Mdm2 turnover also contributes to the control of repeated p53 pulses in response to persistent DNA damage. Our results provide insight into the signaling pathways controlling Mdm2 destruction and further suggest that compromised regulation of Mdm2 results in attenuated p53 activity, thereby facilitating tumor progression.


Cell | 2012

Acetylation-Dependent Regulation of Skp2 Function

Hiroyuki Inuzuka; Daming Gao; Lydia W.S. Finley; Wen Yang; Lixin Wan; Hidefumi Fukushima; Y. Rebecca Chin; Bo Zhai; Shavali Shaik; Alan W. Lau; Zhiwei Wang; Steven P. Gygi; Keiko Nakayama; Julie Teruya-Feldstein; Alex Toker; Marcia C. Haigis; Pier Paolo Pandolfi; Wenyi Wei

Aberrant Skp2 signaling has been implicated as a driving event in tumorigenesis. Although the underlying molecular mechanisms remain elusive, cytoplasmic Skp2 correlates with more aggressive forms of breast and prostate cancers. Here, we report that Skp2 is acetylated by p300 at K68 and K71, which is a process that can be antagonized by the SIRT3 deacetylase. Inactivation of SIRT3 leads to elevated Skp2 acetylation, which leads to increased Skp2 stability through impairment of the Cdh1-mediated proteolysis pathway. As a result, Skp2 oncogenic function is increased, whereby cells expressing an acetylation-mimetic mutant display enhanced cellular proliferation and tumorigenesis in vivo. Moreover, acetylation of Skp2 in the nuclear localization signal (NLS) promotes its cytoplasmic retention, and cytoplasmic Skp2 enhances cellular migration through ubiquitination and destruction of E-cadherin. Thus, our study identifies an acetylation-dependent regulatory mechanism governing Skp2 oncogenic function and provides insight into how cytoplasmic Skp2 controls cellular migration.


Molecular Cell | 2012

Negative Regulation of the Stability and Tumor Suppressor Function of Fbw7 by the Pin1 Prolyl Isomerase

Sang Hyun Min; Alan W. Lau; Tae Ho Lee; Hiroyuki Inuzuka; Shuo Wei; Pengyu Huang; Shavali Shaik; Daniel Yenhong Lee; Greg Finn; Martin Balastik; Chun Hau Chen; Manli Luo; Adriana E. Tron; James A. DeCaprio; Xiao Zhen Zhou; Wenyi Wei; Kun Ping Lu

Fbw7 is the substrate recognition component of the Skp1-Cullin-F-box (SCF)-type E3 ligase complex and a well-characterized tumor suppressor that targets numerous oncoproteins for destruction. Genomic deletion or mutation of FBW7 has been frequently found in various types of human cancers; however, little is known about the upstream signaling pathway(s) governing Fbw7 stability and cellular functions. Here we report that Fbw7 protein destruction and tumor suppressor function are negatively regulated by the prolyl isomerase Pin1. Pin1 interacts with Fbw7 in a phoshorylation-dependent manner and promotes Fbw7 self-ubiquitination and protein degradation by disrupting Fbw7 dimerization. Consequently, overexpressing Pin1 reduces Fbw7 abundance and suppresses Fbw7s ability to inhibit proliferation and transformation. By contrast, depletion of Pin1 in cancer cells leads to elevated Fbw7 expression, which subsequently reduces Mcl-1 abundance, sensitizing cancer cells to Taxol. Thus, Pin1-mediated inhibition of Fbw7 contributes to oncogenesis, and Pin1 may be a promising drug target for anticancer therapy.


Biochimica et Biophysica Acta | 2015

Targeting the ubiquitin pathway for cancer treatment

Jia Liu; Shavali Shaik; Xiangpeng Dai; Qiong Wu; Xiuxia Zhou; Zhiwei Wang; Wenyi Wei

Proteasome-mediated degradation is a common mechanism by which cells renew their intracellular proteins and maintain protein homeostasis. In this process, the E3 ubiquitin ligases are responsible for targeting specific substrates (proteins) for ubiquitin-mediated degradation. However, in cancer cells, the stability and the balance between oncoproteins and tumor suppressor proteins are disturbed in part due to deregulated proteasome-mediated degradation. This ultimately leads to either stabilization of oncoprotein(s) or increased degradation of tumor suppressor(s), contributing to tumorigenesis and cancer progression. Therefore, E3 ubiquitin ligases including the SCF types of ubiquitin ligases have recently evolved as promising therapeutic targets for the development of novel anti-cancer drugs. In this review, we highlighted the critical components along the ubiquitin pathway including E1, E2, various E3 enzymes and DUBs that could serve as potential drug targets and also described the available bioactive compounds that target the ubiquitin pathway to control various cancers.


Molecular Cell | 2010

Rictor Forms a Complex with Cullin-1 to Promote SGK1 Ubiquitination and Destruction

Darning Gao; Lixin Wan; Hiroyuki Inuzuka; Anders H. Berg; Alan Tseng; Bo Zhai; Shavali Shaik; Eric J. Bennett; Adriana E. Tron; Jessica A. Gasser; Alan Lau; Steven P. Gygi; J. Wade Harper; James A. DeCaprio; Alex Toker; Wenyi Wei

The Rictor/mTOR complex (also known as mTORC2) plays a critical role in cellular homeostasis by phosphorylating AGC kinases such as Akt and SGK at their hydrophobic motifs to activate downstream signaling. However, the regulation of mTORC2 and whether it has additional function(s) remain largely unknown. Here, we report that Rictor associates with Cullin-1 to form a functional E3 ubiquitin ligase. Rictor, but not Raptor or mTOR alone, promotes SGK1 ubiquitination. Loss of Rictor/Cullin-1-mediated ubiquitination leads to increased SGK1 protein levels as detected in Rictor null cells. Moreover, as part of a feedback mechanism, phosphorylation of Rictor at T1135 by multiple AGC kinases disrupts the interaction between Rictor and Cullin-1 to impair SGK1 ubiquitination. These findings indicate that the Rictor/Cullin-1 E3 ligase activity is regulated by a specific signal relay cascade and that misregulation of this mechanism may contribute to the frequent overexpression of SGK1 in various human cancers.


Journal of Experimental Medicine | 2012

SCF β-TRCP suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2

Shavali Shaik; Carmelo Nucera; Hiroyuki Inuzuka; Daming Gao; Maija Garnaas; Gregory M. Frechette; Lauren Harris; Lixin Wan; Hidefumi Fukushima; Amjad Husain; Vania Nose; Guido Fadda; Peter M. Sadow; Wolfram Goessling; Trista E. North; Jack Lawler; Wenyi Wei

The E3 ubiquitin ligase β-TRCP, acting in concert with casein kinase I, drives ubiquitination and degradation of VEGFR2, and renders human papillary thyroid cancer cells resistant to the VEGFR2 inhibitor sorafenib.


Molecular Cell | 2011

Cdh1 Regulates Osteoblast Function through an APC/C-Independent Modulation of Smurf1

Lixin Wan; Weiguo Zou; Daming Gao; Hiroyuki Inuzuka; Hidefumi Fukushima; Anders H. Berg; Rebecca Drapp; Shavali Shaik; Dorothy Hu; Chantel Lester; Manuel Eguren; Marcos Malumbres; Laurie H. Glimcher; Wenyi Wei

The APC/Cdh1 E3 ubiquitin ligase plays an essential role in both mitotic exit and G1/S transition by targeting key cell-cycle regulators for destruction. There is mounting evidence indicating that Cdh1 has other functions in addition to cell-cycle regulation. However, it remains unclear whether these additional functions depend on its E3 ligase activity. Here, we report that Cdh1, but not Cdc20, promotes the E3 ligase activity of Smurf1. This is mediated by disruption of an autoinhibitory Smurf1 homodimer and is independent of APC/Cdh1 E3 ligase activity. As a result, depletion of Cdh1 leads to reduced Smurf1 activity and subsequent activation of multiple downstream targets, including the MEKK2 signaling pathway, inducing osteoblast differentiation. Our studies uncover a cell-cycle-independent function of Cdh1, establishing Cdh1 as an upstream component that governs Smurf1 activity. They further suggest that modulation of Cdh1 is a potential therapeutic option for treatment of osteoporosis.


Developmental Cell | 2014

APCCdc20 Suppresses Apoptosis through Targeting Bim for Ubiquitination and Destruction

Lixin Wan; Mingjia Tan; Jie Yang; Hiroyuki Inuzuka; Xiangpeng Dai; Tao Wu; Jia Liu; Shavali Shaik; Guoan Chen; Jing Deng; Marcos Malumbres; Anthony Letai; Marc W. Kirschner; Yi Sun; Wenyi Wei

Anaphase-promoting complex Cdc20 (APC(Cdc20)) plays pivotal roles in governing mitotic progression. By suppressing APC(Cdc20), antimitotic agents activate the spindle-assembly checkpoint and induce apoptosis after prolonged treatment, whereas depleting endogenous Cdc20 suppresses tumorigenesis in part by triggering mitotic arrest and subsequent apoptosis. However, the molecular mechanism(s) underlying apoptosis induced by Cdc20 abrogation remains poorly understood. Here, we report the BH3-only proapoptotic protein Bim as an APC(Cdc20) target, such that depletion of Cdc20 sensitizes cells to apoptotic stimuli. Strikingly, Cdc20 and multiple APC-core components were identified in a small interfering RNA screen that, upon knockdown, sensitizes otherwise resistant cancer cells to chemoradiation in a Bim-dependent manner. Consistently, human adult T cell leukemia cells that acquire elevated APC(Cdc20) activity via expressing the Tax viral oncoprotein exhibit reduced Bim levels and resistance to anticancer agents. These results reveal an important role for APC(Cdc20) in governing apoptosis, strengthening the rationale for developing specific Cdc20 inhibitors as effective anticancer agents.

Collaboration


Dive into the Shavali Shaik's collaboration.

Top Co-Authors

Avatar

Wenyi Wei

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar

Hiroyuki Inuzuka

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar

Lixin Wan

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar

Daming Gao

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar

Hidefumi Fukushima

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Pengda Liu

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar

Alan W. Lau

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar

John M. Asara

Beth Israel Deaconess Medical Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge